Unity Biotech reports FY 2023 net loss $39.9M; Phase 2b ASPIRE DME study upsized to 50 patients

Unity Biotechnology, Inc.

2024-Q1 EPS reported -$0.34

Cash, equivalents and marketable securities $43.2M as of Dec 31, 2023; runway into Q3 2025.
Net loss FY 2023 $39.9M (down from $44.5M in 2022); Q4 net loss $4.3M (down from $7.4M).
R&D expenses decreased $16.8M to $20.1M in FY 2023 due to completion of BEHOLD/ENVISION studies and headcount reduction.
Phase 2b ASPIRE study in DME (UBX1325 vs aflibercept) upsized to 50 patients; 16-week data expected Q4 2024, 24-week data Q1 2025.
Published research in Nature Medicine in Jan 2024 on targeting cellular senescence in DME.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Unity Biotechnology, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the twelve months ended December 31, 2023 was $39.9 million.

Period: fourth quarter and full year ended December 31, 2023
Net income: Net loss for the twelve months ended December 31, 2023 was $39.9 million
Result: reported results

Exact text from the filing

On April 15, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

322 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-044230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.